Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant, revealing the structural basis for venetoclax resi...
Guardado en:
Autores principales: | Richard W. Birkinshaw, Jia-nan Gong, Cindy S. Luo, Daisy Lio, Christine A. White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen, Andrew W. Roberts, David C. S. Huang, Peter M. Colman, Peter E. Czabotar |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/972a06d765d140d0b0bfb95c8133217b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
por: Sylvain Garciaz, et al.
Publicado: (2021) -
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Carmen D. Herling, et al.
Publicado: (2018) -
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber M, et al.
Publicado: (2019) -
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Richa Bajpai, et al.
Publicado: (2020) -
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
por: Fariba Némati, et al.
Publicado: (2014)